BACKGROUND: The rate of radiation p

BACKGROUND: The rate of radiation pneumonitis (RP) for patients receiving chemoradiotherapy has been various across studies. Whether it is related to different chemotherapy schedules used in combination with radiation therapy were evaluated in this study. New factors associated with RP were also investigated. METHODS AND MATERIALS: A total of 369 consecutive patients with Stage III non small cell lung cancer treated with chemoradiotherapy were followed after radiotherapy (RT). Among them 262 patients received concurrent chemoradiotherapy followed by consolidation chemotherapy and 107 patients received only sequential chemotherapy after RT. RP was graded according to Common Terminology Criteria for Adverse Events version 4.0. RESULTS: The rate of grade >/= 2 were 39.7%, 31% and 33.6% in the concurrent DP (docetaxel/cisplatin), concurrent NP (vinorelbine/cisplatin) and sequential group, and grade >/= 3 RP were 18.4%, 9.5%, and 11.2% respectively. The rate of grade >/= 3 RP was significantly higher in concurrent DP group than that in concurrent NP group (p = 0.04). RP occurred earlier in concurrent DP group than that in the other two groups. There were no significant differences in response rate among the three groups. In the multivariate analysis, age (OR = 1.99, p = 0.038 and OR = 8.90, p < 0.001), chemotherapy schedule (OR = 1.45, p = 0.041 and OR = 1.98, p = 0.013), mean lung dose(OR = 1.42, p < 0.001 and OR = 1.64, p < 0.001), and planning target volume(OR = 1.004, p = 0.001 and OR = 1.005, p = 0.021) were predictors for both grade >/= 2 and grade >/= 3 RP. Response to treatment was a new predictor for grade >/= 3 RP only (OR = 4.39, p = 0.034). CONCLUSIONS: Response to treatment was found to be a new predictor for grade >/= 3 RP. Compared to concurrent NP schedule, concurrent DP schedule achieved similar response to treatment but resulted in a higher risk of grade >/= 3 RP.

結果 (中文) 1:

背景︰ 放射性肺炎 (RP) 患者放、 化疗的率一直各种跨研究。是否它关系到这项研究评价不同化疗时间表与放射治疗结合使用。此外考察了与 RP 相关联的新因素。方法和材料︰ 共 369 连续患者第三期非小细胞肺癌化疗后放疗 (RT)。262 例收到同时放化疗的巩固化疗和 107 病人收到只有序贯化疗后室温 RP 为 4.0 版的不良事件分级根据共同的术语标准。结果︰ 等级率 > / = 2 为 39.7%、 31%和 33.6%的并发 DP （多西紫杉醇/顺铂）、 并发 NP （长春瑞滨/顺铂） 和序贯组、 年级 > / = 3 RP 分别为 18.4%、 9.5%和 11.2%。级率 > = 3 / RP 较显著高于并发 DP 组中，并发 NP 组 (p = 0.04)。RP 早些时候发生并发 DP 组优于其他两组。有了答复率三组间无显著差异。在多变量分析中，年龄 (或 = 1.99，p = 0.038 和或 = 8.90，p < 0.001)，化疗附表 (OR = 1.45，p = 0.041 和或 = 1.98，p = 0.013)、 平均肺剂量 （= 1.42，p < 0.001 或 = 1.64，p < 0.001），和规划目标卷 (OR = 1.004，p = 0.001 和或 = 1.005，p = 0.021) 显著的预测作用这两个年级 > / = 2 和等级 > / = 3 RP。对治疗的反应是一个等级的新预测 > / = 3 RP 只 (OR = 4.39，p = 0.034)。结论︰ 对治疗的反应被发现，是一个新的预测，年级 > / = 3 RP。与并发 NP 时间表相比，并发 DP 时间表取得类似对治疗的反应，但导致更高风险等级的 > / = 3 RP。

結果 (中文) 2:

背景：放射性肺炎（RP），用于接收放化疗患者的速度已经跨越各种研究。无论是涉及在与放射治疗组合使用不同的化疗时间表在这项研究中进行评价。与RP相关的新的因素也进行了研究。材料与方法：与放化疗治疗Ⅲ期非小细胞肺癌患者一共有369个连续放疗的患者（RT）后随访。其中262例患者接受放疗同期化疗加巩固化疗和107例患者放疗后只收到了序贯化疗。RP根据通用术语标准不良事件4.0版分级。结果：等级> / = 2分别为39.7％，31％和并发DP（多西他赛/顺铂）33.6％，同时NP（长春瑞滨/顺铂）和顺序组，等级> / = 3 RP分别为18.4％的速度，9.5％，和11.2％。等级> / = 3 RP率为并发DP组较同期NP组（p = 0.04）在显著高。RP并发DP组较早期发生在其它两个组。有响应率三组间无显著差异。在多变量分析中，年龄（OR = 1.99，P = 0.038和OR = 8.90，P <0.001），化疗时间表（OR = 1.45，P = 0.041和OR = 1.98，P = 0.013），平均肺剂量（OR = 1.42，p <0.001及OR = 1.64，p <0.001），计划靶区（OR = 1.004，p = 0.001及OR = 1.005，p = 0.021）是两个档次的预测> / = 2级> / = 3 RP。对治疗的反应是等级> / = 3只RP了新的预测因子（OR = 4.39，P = 0.034）。结论：对治疗的反应被认为是对品位> / = 3 RP了新的预测。相比于并发NP进度，同时DP时间表实现对治疗的反应相似，但造成了等级> / = 3 RP的风险较高。

結果 (中文) 3:

背景：放射性肺炎的发生率（RP）患者接受放化疗已被各种不同研究。是否涉及到不同的化疗计划与放射治疗相结合使用在这项研究中进行了评价。与反相的新的因素进行了研究。材料和方法：共与放化疗治疗Ⅲ期非小细胞肺癌的369例患者进行放疗（RT）。其中262例患者接受同步放化疗后RT. RP根据常用术语标准不良事件的4版分级巩固化疗，107例患者接受序贯化疗。结果：年级> / = 2率为39.7%、31%和33.6%的同步DP（多西紫杉醇/顺铂），并发NP（长春瑞滨联合顺铂）和序贯组和年级> / = 3 RP为18.4%，9.5%，和11.2%。等级> / = 3反相率同步DP组显著高于同期NP组（P = 0.04）。RP发生同步DP组比其他两组早。三组患者的反应率无显著性差异。在多变量分析中，年龄（OR = 1.99，P = 0.038或= 8.90，P＜0.001），化疗方案（或= 1.45，P = 0.041或= 1.98，P = 0.013），平均肺剂量（OR＝1.42，P＜0.001或＝1.64，P＜0.001），和计划靶体积（或= 1.004，P = 0.001或= 1.005，P = 0.021）预测为等级2和等级> > / = / = 3 RP的治疗反应是一种新的预测等级> / = 3 RP只（或= 4.39，P = 0.034）。结论：对治疗的反应被认为是品位> / = 3 RP的一个新的预测相比，并发NP进度，进度达到同步DP治疗相似的反应，但在一个较高的等级> / = 3 RP的风险